In February 2015, palbociclib received accelerated approval from the FDA in combination with letrozole for the treatment of postmenopausal women with ER+, HER2– advanced breast cancer as initial endocrine therapy for metastatic disease. The gene discussed is ERBB2; the disease is breast carcinoma.